Nanobiotix S.A. (NBTX)
NASDAQ: NBTX
· Real-Time Price · USD
19.70
-0.18 (-0.91%)
At close: Oct 03, 2025, 2:29 PM
-0.91% (1D)
| Bid | 19.64 |
| Market Cap | 944.02M |
| Revenue (ttm) | -11.61M |
| Net Income (ttm) | -68.13M |
| EPS (ttm) | -1.28 |
| PE Ratio (ttm) | -15.39 |
| Forward PE | 170.36 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 19.97 |
| Volume | 47,291 |
| Avg. Volume (20D) | 41,377 |
| Open | 19.95 |
| Previous Close | 19.88 |
| Day's Range | 19.11 - 20.09 |
| 52-Week Range | 2.76 - 21.12 |
| Beta | 0.69 |
| Ex-Dividend Date | n/a |
About NBTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NBTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NBTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 days ago
+4.83%
Nanobiotix shares are trading higher after the com...
Unlock content with
Pro Subscription
2 weeks ago
+20.69%
Nanobiotix shares are trading higher after the company announced new results focused on patients with primary cutaneous melanoma from the ongoing Phase 1 Study 1100 evaluating JNJ-1900 in combination with immune checkpoint inhibitors for patients with advanced cancers.
2 weeks ago · seekingalpha.com
Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull CaseNanobiotix S.A. stock has surged after strong Phase 1 data for NBTXR3 in anti-PD-1 resistant melanoma, showing high response and disease control rates. NBTX's partnership with Janssen could yield up t...
